SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced a study demonstrating how its Decipher® Prostate Cancer Classifier was used in a community based health care setting to accurately predict metastasis in patients who had undergone prostate removal surgery. The study was presented today at the Society of Urologic Oncology’s 16th Annual Meeting, held in Washington, D.C.
“The results of this study reinforce Decipher utility for patients treated in a community based health care setting,” said Doug Dolginow, M.D., chief executive officer of GenomeDx. “The study adds to an already large body of data supporting the ability of Decipher to stratify patients who are at low and high risk of recurrence.”
The study, conducted at Kaiser Permanente Northwest, evaluated the Decipher scores and disease progression of 224 men treated who did not receive radiation therapy up to six months following prostate removal surgery. At ten years post-prostatectomy, the metastasis rate was 2.6% for patients who had received a low Decipher score, and 13.4% for patients with high Decipher scores. In combination with standard risk models such as CAPRA-S, Decipher further improved prediction of metastasis (c-index 0.84) compared to use of CAPRA-S alone (c-index 0.73).
About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.
Learn more at www.DecipherTest.com
About Decipher GRIDTM
The Decipher Genomic Resource Information Database (Decipher GRID) is the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient’s whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.
Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx’s Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRIDTM, the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.
Learn more at www.GenomeDx.com
Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-supports-use-of-genomedxs-decipher-prostate-cancer-classifier-in-a-community-based-health-care-setting-300187217.html
SOURCE GenomeDx Biosciences
